Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase.

Kelly MP, Jungbluth AA, Wu BW, Bomalaski J, Old LJ, Ritter G.

Br J Cancer. 2012 Jan 17;106(2):324-32. doi: 10.1038/bjc.2011.524. Epub 2011 Dec 1.

2.

Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis.

Kim RH, Coates JM, Bowles TL, McNerney GP, Sutcliffe J, Jung JU, Gandour-Edwards R, Chuang FY, Bold RJ, Kung HJ.

Cancer Res. 2009 Jan 15;69(2):700-8. doi: 10.1158/0008-5472.CAN-08-3157.

3.

Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase.

Feun LG, Marini A, Walker G, Elgart G, Moffat F, Rodgers SE, Wu CJ, You M, Wangpaichitr M, Kuo MT, Sisson W, Jungbluth AA, Bomalaski J, Savaraj N.

Br J Cancer. 2012 Apr 24;106(9):1481-5. doi: 10.1038/bjc.2012.106.

4.

Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis.

Delage B, Luong P, Maharaj L, O'Riain C, Syed N, Crook T, Hatzimichael E, Papoudou-Bai A, Mitchell TJ, Whittaker SJ, Cerio R, Gribben J, Lemoine N, Bomalaski J, Li CF, Joel S, Fitzgibbon J, Chen LT, Szlosarek PW.

Cell Death Dis. 2012 Jul 5;3:e342. doi: 10.1038/cddis.2012.83.

5.

Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase.

Bowles TL, Kim R, Galante J, Parsons CM, Virudachalam S, Kung HJ, Bold RJ.

Int J Cancer. 2008 Oct 15;123(8):1950-5. doi: 10.1002/ijc.23723.

6.

Arginine deprivation as a targeted therapy for cancer.

Feun L, You M, Wu CJ, Kuo MT, Wangpaichitr M, Spector S, Savaraj N.

Curr Pharm Des. 2008;14(11):1049-57. Review.

7.

Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells.

Manca A, Sini MC, Izzo F, Ascierto PA, Tatangelo F, Botti G, Gentilcore G, Capone M, Mozzillo N, Rozzo C, Cossu A, Tanda F, Palmieri G.

Oncol Rep. 2011 Jun;25(6):1495-502. doi: 10.3892/or.2011.1220. Epub 2011 Mar 18.

PMID:
21424129
8.

Argininosuccinate synthetase (ASS) deficiency in high-grade pulmonary neuroendocrine carcinoma: an opportunity for personalized targeted therapy.

Walts AE, Bomalaski JS, Ines D, Orsulic S.

J Cancer Res Clin Oncol. 2015 Aug;141(8):1363-9. doi: 10.1007/s00432-014-1904-z. Epub 2014 Dec 30.

PMID:
25548129
9.
10.
11.

The relationship of arginine deprivation, argininosuccinate synthetase and cell death in melanoma.

Savaraj N, Wu C, Kuo MT, You M, Wangpaichitr M, Robles C, Spector S, Feun L.

Drug Target Insights. 2007;2:119-28. Epub 2007 Jun 15.

12.

Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling.

Liu J, Ma J, Wu Z, Li W, Zhang D, Han L, Wang F, Reindl KM, Wu E, Ma Q.

BMC Cancer. 2014 Sep 20;14:686. doi: 10.1186/1471-2407-14-686.

13.

Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma.

Syed N, Langer J, Janczar K, Singh P, Lo Nigro C, Lattanzio L, Coley HM, Hatzimichael E, Bomalaski J, Szlosarek P, Awad M, O'Neil K, Roncaroli F, Crook T.

Cell Death Dis. 2013 Jan 17;4:e458. doi: 10.1038/cddis.2012.197.

14.

Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin.

Savaraj N, Wu C, Li YY, Wangpaichitr M, You M, Bomalaski J, He W, Kuo MT, Feun LG.

Oncotarget. 2015 Mar 20;6(8):6295-309.

15.

ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance.

Huang HY, Wu WR, Wang YH, Wang JW, Fang FM, Tsai JW, Li SH, Hung HC, Yu SC, Lan J, Shiue YL, Hsing CH, Chen LT, Li CF.

Clin Cancer Res. 2013 Jun 1;19(11):2861-72. doi: 10.1158/1078-0432.CCR-12-2641. Epub 2013 Apr 2.

16.

Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo.

Fiedler T, Strauss M, Hering S, Redanz U, William D, Rosche Y, Classen CF, Kreikemeyer B, Linnebacher M, Maletzki C.

Cancer Biol Ther. 2015;16(7):1047-55. doi: 10.1080/15384047.2015.1026478. Epub 2015 Mar 16.

17.
18.

Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging.

Allen MD, Luong P, Hudson C, Leyton J, Delage B, Ghazaly E, Cutts R, Yuan M, Syed N, Lo Nigro C, Lattanzio L, Chmielewska-Kassassir M, Tomlinson I, Roylance R, Whitaker HC, Warren AY, Neal D, Frezza C, Beltran L, Jones LJ, Chelala C, Wu BW, Bomalaski JS, Jackson RC, Lu YJ, Crook T, Lemoine NR, Mather S, Foster J, Sosabowski J, Avril N, Li CF, Szlosarek PW.

Cancer Res. 2014 Feb 1;74(3):896-907. doi: 10.1158/0008-5472.CAN-13-1702. Epub 2013 Nov 27.

19.

Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma.

Savaraj N, You M, Wu C, Wangpaichitr M, Kuo MT, Feun LG.

Curr Mol Med. 2010 Jun;10(4):405-12. Review.

20.

ADI, autophagy and apoptosis: metabolic stress as a therapeutic option for prostate cancer.

Kim RH, Bold RJ, Kung HJ.

Autophagy. 2009 May;5(4):567-8. Epub 2009 May 20.

Items per page

Supplemental Content

Write to the Help Desk